NCT07927036
Enhancing the Effect of Stellate Ganglion Block in the Treatment of PTSD: Bupivacaine vs Bupivacaine + Ketamine
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Interventions modified
- Secondary endpoints revised (4)
- Study title shortened, about 8 words
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
One dose of 6mL 0.5% bupivacaine combined with 2ml normal saline. The dose and medication provided to Group 1 is in line with current research practice for SGB which suggests a dosage between 6mL and 9 mL of local anaesthetic. Saline is included in the injection to match the volume of the injection for Group 2 without adding additional medical properties to the solution.
The bupivacaine dose administered to Group 2 is identical to that administered to Group 1, with the addition of 20 mg ketamine (2 mL of a 10 mg/mL solution). A fixed ketamine dose of 20 mg was selected to approximate a low-dose (subanesthetic) exposure of 0.3 mg/kg in a 70 kg adult (21 mg), while allowing standardized dosing across participants. This dose was chosen to remain within a range commonly used in clinical research investigating the analgesic and neuropsychiatric effects of ketamine. This is the accepted standard and widely used dose in clinical practice.
Participants selected to this group will not receive any intervention and continue with their treatments as usual.
Combination products: SGB - Combined Solution of Bupivacaine + Saline, SGB - Combined Solution of Bupivacaine + Ketamine Adjuvant
Sites
1 site in 1 country
- The RoyalOttawa, Ontario, Canada